Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial

Abstract

This investigation was conducted to evaluate comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome (PCOS). This randomized controlled trial was conducted on 53 women with PCOS, aged 18–40 years old. Subjects were randomly allocated into two groups to take either myo-inositol (n = 26) or metformin (n = 27) for 12 weeks. Myo-inositol supplementation, compared with metformin, significantly reduced fasting plasma glucose (FPG) (β −5.12 mg/dL; 95% CI, −8.09, −2.16; p=.001), serum insulin levels (β −1.49 µIU/mL; 95% CI, −2.28, −0.70; p<.001), homeostasis model of assessment-insulin resistance (β −0.36; 95% CI, −0.55, −0.17; p<.001), serum triglycerides (β 12.42 mg/dL; 95% CI, −20.47, −4.37; p=.003) and VLDL-cholesterol levels (β −2.48 mg/dL; 95% CI, −4.09, −0.87; p=.003), and significantly increased the quantitative insulin sensitivity check index (β 0.006; 95% CI, 0.002, 0.01; p=.006) compared with metformin. Moreover, myo-inositol supplementation upregulated gene expression of peroxisome proliferator-activated receptor gamma (PPAR-γ) (p=.002) compared with metformin. Overall, taking myo-inositol, compared with metformin, for 12 weeks by women with PCOS had beneficial effects on glycemic control, triglycerides and VLDL-cholesterol levels, and gene expression of PPAR-γ.

摘要

本研究旨在比较肌醇和二甲双胍对多囊卵巢综合征（PCOS）女性血糖控制、血脂谱以及与胰岛素和脂质代谢相关基因表达的影响。这项随机对照试验的研究对象为53名年龄在18-40岁的PCOS女性。将受试者随机分成两组, 分别服用肌醇（n = 26）或二甲双胍（n = 27）12周。与二甲双胍相比, 肌醇的补充显著降低空腹血糖（FPG）（β-5.12 mg / dL; 95%CI, -8.09, -2.16; p = .001）, 血清胰岛素水平（β-1.4.49 mIU / mL; 95%CI,-2.28, -0.70; p <.001）, 评估胰岛素抵抗的稳态模型（β-0.36; 95%CI,-0.55,-0.17; p <.001）, 血清甘油三酯（β 12.42 mg / dL; 95%CI, -20.47, -4.37; p = .003）和VLDL-胆固醇水平（β-2.48 mg / dL; 95%CI, -4.09, -0.87; p = .003）, 显著增加定量胰岛素敏感性检查指数（β 0.006; 95%CI, 0.002,0.01; p = .006）。此外, 与二甲双胍相比, 肌醇补充可以上调过氧化物酶增殖物激活受体γ（PPAR-c）的基因表达（p = .002）。总体而言, 与二甲双胍相比, PCOS女性服用肌醇持续12周, 有益于对血糖, 甘油三酯和VLDL-胆固醇水平的控制以及PPAR-c的基因表达。

The Chinese abstracts are translated by Prof. Dr. Xiangyan Ruan and her team: Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China.

Keywords:

• Myo-inositol
• metformin
• glycemic control
• lipid profiles
• polycystic ovary syndrome

Acknowledgements

The authors would like to thank the staff of Kosar Clinic (Arak, Iran) for their assistance in this project.

Disclosure statement

No potential conflict of interest was reported by the author(s).